Neurologic Evaluation of Patients After Transapical Beating-Heart Septal Myectomy
Launched by XIANG WEI · Oct 8, 2023
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a new heart surgery called transapical beating-heart septal myectomy on the brain and nervous system of patients. The main goal is to find out if this surgery causes any neurological problems, like changes in thinking or memory, compared to other types of heart surgeries. Participants in the study will undergo thorough brain and cognitive tests before the surgery, right after, and again 30 days later to see how well their brain is functioning and to check for any brain changes using advanced imaging techniques.
To be eligible for this trial, participants should have conditions that require the transapical beating-heart septal myectomy or similar heart surgeries, like hypertrophic obstructive cardiomyopathy, and be willing to attend follow-up evaluations. However, individuals with recent severe brain issues, certain medical implants, or those unable to undergo brain scans would not qualify. If you decide to participate, you can expect careful monitoring of your neurological health throughout the study, helping researchers understand the safety of this innovative surgery for both the heart and the brain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • meets indications for transapical beating-heart septal myectomy procedure or these cardiac surgery involving left heart operation, such as hypertrophic obstructive cardiomyopathy, mitral valve prolapse, and ventricular septal defect; willing to comply with protocol-specified follow-up evaluations.
- Exclusion Criteria:
- • severe brain infarction, such stroke and cerebral hemorrhage recently; the implantation of metal materials, including Pacemaker; not able to undergo MRI examination; peptic ulcer or recent gastrointestinal bleeding (\<6 months); the history of myocardial infarction; cognitive impairment in the past; not able to finish nervous system evaluation scale.
About Xiang Wei
Xiang Wei is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a strong focus on developing novel therapies, the organization collaborates with a diverse network of healthcare professionals and institutions to conduct rigorous clinical studies across various therapeutic areas. Committed to ethical practices and patient-centered approaches, Xiang Wei emphasizes transparency and scientific integrity in all its initiatives, striving to bring safe and effective treatments to market. Through its comprehensive expertise and a robust infrastructure, Xiang Wei aims to enhance healthcare outcomes and contribute to the global understanding of complex diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Xiang Wei, M.D.
Study Chair
Tongji Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported